Non-small cell lung cancer (NSCLC) is a major public health problem, accounting from more cancer-related deaths than any other cancer. Both immunotherapy, based on the expression of tumor-specific antigens, and targeted therapy, based on the presence of oncogenic mutations, are under development in NSCLC. In this study, we analyzed the expression of MAGE-A, of the CTA group, in tumors from a cohort of resected NSCLC with respect to their clinicopathological characteristics and to the mutational status of the EGFR and KRAS genes. We found MAGE-A expression, by immunohistochemistry, in 43% of the tumors. MAGE-A expression was significantly more frequent in squamous than in adenous tumors, did not correlate with disease stage, but was significantly correlated with high tumor grade and poorer survival. EGFR and KRAS mutations were present in adenous, but not in squamous tumors. Whereas the presence of EGFR mutations did not appear to impact survival, that of KRAS mutations was associated with early stage disease and better survival. MAGE-A expression was absent from KRAS mutated adenous tumors, but was not significantly different in tumors bearing or not EGFR mutations. Altogether, the reported results provide guidance for the design of combination therapies in patients with NSCLC.
- Received December 2, 2013.
- Revision received April 24, 2014.
- Accepted May 9, 2014.
- Copyright © 2014, American Association for Cancer Research.